Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Jagsonpal Pharmaceuticals reported strong Q1 Jun-2025 results.
- Organic growth was between 9% and 10%.
- Yash Pharma contributed approximately 120 million INR to the top line, compared to 35 million INR in the same quarter last year.
- The company maintained its market share in most of its top 15 brands, except for one product where it chose to prioritize pricing over volume.
- The company is generating approximately 50 million INR in cash every month.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.